Go Pro
→ [URGENT] Mode Mobile terms changing Aug 14 (From Mode Mobile) (Ad)tc pixel
NASDAQ:CALC

CalciMedica Q2 2025 Earnings Report

CalciMedica logo
$0.80 +0.04 (+5.75%)
As of 02:10 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

CalciMedica EPS Results

Actual EPS
-$0.40
Consensus EPS
-$0.40
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

CalciMedica Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

CalciMedica Announcement Details

Quarter
Q2 2025
Date
8/12/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

CalciMedica's next earnings date is estimated for Tuesday, August 11, 2026, based on past reporting schedules.

Conference Call Resources

CalciMedica Earnings Headlines

CalciMedica, Inc.: CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational Endpoints
July 29, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-07/69155305-calcimedica-inc-calcimedica-announces-fda-alignment-on-phase-2b-trial-design-for-auxora-in-acute-pancreatitis-and-identifies-disease-s-first-potent-008.htm
CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational Endpoints
July 29, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/calcimedica-announces-fda-alignment-on-phase-2b-trial-design-for-auxora-in-acute-pancreatitis-and-identifies-diseases-first-potential-registrational-endpoints-302837341.html
Only one company survived this screen
On May 21, 2026, a federal board voted unanimously to lend one gold company roughly $3 billion. The company passed a strict four box screen: American soil, full permits, meaningful scale, and small enough that the capital transforms it. Majors like Newmont failed on scale; juniors failed on permits. It trades at about 1/50th the size of Newmont, with final loan papers expected in the second half of 2026.tc pixel
August 4 at 1:00 AM  |  Behind the Markets (Ad)
CalciMedica, Inc.: CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data
June 25, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-06/68852934-calcimedica-inc-calcimedica-announces-clinical-development-of-auxora-may-proceed-following-fda-review-of-kourage-trial-interim-safety-data-008.htm
Analysts Offer Insights on Healthcare Companies: OnKure Therapeutics (OKUR) and CalciMedica (CALC)
June 25, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/351/analysts-offer-insights-on-healthcare-companies-onkure-therapeutics-okur-and-calcimedica-calc/
CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program
June 24, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/calcimedica-announces-private-placement-financing-for-up-to-approximately-49-million-to-advance-pulmonary-hypertension-program-302808596.html
See More CalciMedica Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CalciMedica? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CalciMedica and other key companies, straight to your email.

About CalciMedica

CalciMedica (NASDAQ:CALC), Inc. (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia. Early-phase data suggest that CRAC channel inhibition can reduce inflammatory cytokine release and support organ function in critically ill patients.

CalciMedica pursues a development strategy that combines rigorous clinical evaluation with strategic collaborations to expedite potential regulatory approvals and commercialization. Operating primarily in the United States, the company works closely with academic centers and healthcare organizations to advance its pipeline. By targeting calcium signaling in innate immune cells, CalciMedica aims to fill unmet medical needs in acute inflammatory diseases and improve outcomes for high-risk patient populations.

View CalciMedica Profile
Earnings Tools